Fungal pathogens are responsible for a large number of mild to severe infections worldwide resulting in 1.6 million deaths. With the rapid emergence of drug resistance, the treatment of fungal infections is rapidly becoming unmanageable. Thus, the discovery and development of novel antifungal drugs is an unmet need of the hour. In this context, ibrexafungerp (SCY-078; SCYNEXIS) is the first orally bioavailable agent that has activity against beta-glucan synthase, an essential component of the cell wall. It has broad-spectrum activity against a wide range of Candida sp, including those that are resistant to echinocandins. In addition, ibrexafungerp exhibits broad-spectrum fungicidal activity including against multidrug-resistant strains, possesses high tissue penetration and exhibits flexible dosing options including via oral and intravenous routes. The U.S. Food and Drug Administration has granted both qualified infectious disease product and fast track designations for the oral formulation of ibrexafungerp for the treatment and prevention of recurrent vulvovaginal candidiasis.
Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.